Abstract:Therapeutic strategies that induce inflammatory responses in immunologically "cold" tumors have the potential to improve immunotherapeutic outcomes. Pharmacologically activating the stimulator of interferon gene (STING) pathway induces innate immunity, subsequently enhancing tumor immunogenicity. Here, we developed a nanoadjuvant with tumor-restricted pharmacology that rapidly activated STING and reshaped the tumor microenvironment. The non-nucleotide STING agonist MSA-2 was chemically engineered with a piperazine motif linked by a saturated hydrocarbon chain of varying lengths to produce ionizable prodrugs that were further developed into nanoadjuvants. Compared with state-of-the-art liposomes, the nanoadjuvant displayed prolonged retention in the circulation and improved intratumoral delivery. In the acidic tumor microenvironment, the nanoadjuvant underwent polyethylene glycol deshielding, enabling efficient extravasation and penetration into tumors. Concomitantly, the STING prodrug escaped from the endo/lysosome compartment to partition into the cytosol for spontaneous esterase-catalyzed drug activation. In mouse models of syngeneic and chemically induced colorectal cancers, nanoparticle treatment provoked robust STING-mediated antitumor immunity, shifting the tumor immune landscape from immunosuppressed to tumoricidal. Additionally, the nanoadjuvant demonstrated antitumor efficacy in triple-negative breast cancer, which was further enhanced by the addition of immune checkpoint inhibitors. Collectively, this study demonstrates the safety and immune-stimulating effects of a STING-activating nanoadjuvant, supporting the clinical evaluation of this STING immunotherapeutic alone and in combination with other immunotherapies. Significance: STING-activating nanoadjuvants rationally engineered using an ionizable prodrug approach for systemic administration are well-tolerated and yield durable antitumor immune responses, providing a potential immunotherapeutic strategy to improve cancer treatment.

Activating Innate Immunity by a STING Signal Amplifier for Local and Systemic Immunotherapy

Tumor Microenvironment‐Responsive Nanoparticles Amplifying STING Signaling Pathway for Cancer Immunotherapy

Ionizable STING-Activating Nanoadjuvants Enhance Tumor Immunogenicity and Potentiate Immunotherapy Efficacy in Solid Tumors

Potentiating the Systemic Immunity by Bacteria‐Delivered Sting Activation in a Tumor Microenvironment

A Bi-Adjuvant Nanovaccine Amplifying STING Activation for Cancer Immunotherapy

Advanced nanomaterials targeting activation of STING for enhanced cancer immunotherapy

Engineering the Immune Adaptor Protein STING as a Biologic

Novel Emerging Nano-Assisted Anti-Cancer Strategies Based on the STING Pathway

Tumor-responsive Covalent Organic Polymeric Nanoparticles Enhancing STING Activation for Cancer Immunotherapy

STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy

Amplifying STING activation by cyclic dinucleotide–manganese particles for local and systemic cancer metalloimmunotherapy

Activation of Stimulation of Interferon Genes (STING) Signal and Cancer Immunotherapy

Nanomaterial-encapsulated STING agonists for immune modulation in cancer therapy

Engineering the Immune Adaptor Protein STING as a Functional Carrier

Targeting STING signaling for the optimal cancer immunotherapy

Bioactivable Sting Nanoagonists to Synergize Nir‐Ii Mild Photothermal Therapy Primed Robust and Long‐Term Anticancer Immunity

Sono-Driven STING Activation Using Semiconducting Polymeric Nanoagonists for Precision Sono-Immunotherapy of Head and Neck Squamous Cell Carcinoma

Enhanced Tumor Immunotherapy by Triple Amplification Effects of Nanomedicine on the STING Signaling Pathway in Dendritic Cells

Targeted Delivery of STING Agonist via Albumin Nanoreactor Boosts Immunotherapeutic Efficacy against Aggressive Cancers

Multifunctional STING-Activating Mn3 O4 @Au-Dsdna/dox Nanoparticle for Antitumor Immunotherapy.

Clinical applications of STING agonists in cancer immunotherapy: current progress and future prospects